Patient adherence to subcutaneous IFN beta-1a injections using the RebiSmart® injection device: a retrospective real-world study among Dutch and German patients with multiple sclerosis
Marieke Krol,1 Gert de Voer,2 Ulrike Osowski3 1QuintilesIMS, Capelle aan den Ijssel, the Netherlands; 2Merck B.V., Schiphol-Rijk, the Netherlands; 3Merck KGaA, Darmstadt, Germany Purpose: Long-term treatment adherence among patients with multiple sclerosis (MS) is a general concern, with an establ...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2017-07-01
|
| Series: | Patient Preference and Adherence |
| Subjects: | |
| Online Access: | https://www.dovepress.com/patient-adherence-to-subcutaneous-ifn-beta-1a-injections-using-the-reb-peer-reviewed-article-PPA |
| _version_ | 1830285388295438336 |
|---|---|
| author | Krol M de Voer G Osowski U |
| author_facet | Krol M de Voer G Osowski U |
| author_sort | Krol M |
| collection | DOAJ |
| description | Marieke Krol,1 Gert de Voer,2 Ulrike Osowski3 1QuintilesIMS, Capelle aan den Ijssel, the Netherlands; 2Merck B.V., Schiphol-Rijk, the Netherlands; 3Merck KGaA, Darmstadt, Germany Purpose: Long-term treatment adherence among patients with multiple sclerosis (MS) is a general concern, with an established correlation with clinical efficacy. Closely monitoring patients’ treatment behavior may have a beneficial effect on adherence. This study assessed adherence, in daily life, to subcutaneous (sc) IFN beta-1a, self-administered using the RebiSmart® electronic injection device (the IFN beta-Ia autoinjector device), in patients with MS. Patients and methods: This was a retrospective observational study analyzing treatment adherence based on injection data, eg, injection date and dose, extracted from the IFN beta-Ia autoinjector devices collected from patients in Germany and the Netherlands. Results: Data recorded in the period from 2007 to 2012 by the IFN beta-Ia autoinjector devices from 1,682 (79.7% from Germany, 20.3% from the Netherlands) patients were analyzed. A mean of 94.8% of the multi-dose cartridges (containing sc IFN beta-1a for three injections) were used completely, indicating a low incidence of application errors and drug wastage. The mean adherence rate was 90.7% and 82.9% over the entire observation period (mean treatment duration: 150.1 weeks). Median adherence rates were similar between German and Dutch patients (97.9% vs 99.0%). Conclusion: In daily clinical practice, patients using the IFN beta-Ia autoinjector device were highly adherent to sc IFN beta-1a. The injection data stored electronically in the device may help patients to adhere to treatment regimens and, if viewed by physicians, promote discussion of adherence issues with patients. Keywords: multiple sclerosis, injection device, IFN beta-1a, observational study |
| first_indexed | 2024-12-19T03:38:20Z |
| format | Article |
| id | doaj.art-354a03eb59f54bf3a6bcba3ab9fed5db |
| institution | Directory Open Access Journal |
| issn | 1177-889X |
| language | English |
| last_indexed | 2024-12-19T03:38:20Z |
| publishDate | 2017-07-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Patient Preference and Adherence |
| spelling | doaj.art-354a03eb59f54bf3a6bcba3ab9fed5db2022-12-21T20:37:19ZengDove Medical PressPatient Preference and Adherence1177-889X2017-07-01Volume 111189119633712Patient adherence to subcutaneous IFN beta-1a injections using the RebiSmart® injection device: a retrospective real-world study among Dutch and German patients with multiple sclerosisKrol Mde Voer GOsowski UMarieke Krol,1 Gert de Voer,2 Ulrike Osowski3 1QuintilesIMS, Capelle aan den Ijssel, the Netherlands; 2Merck B.V., Schiphol-Rijk, the Netherlands; 3Merck KGaA, Darmstadt, Germany Purpose: Long-term treatment adherence among patients with multiple sclerosis (MS) is a general concern, with an established correlation with clinical efficacy. Closely monitoring patients’ treatment behavior may have a beneficial effect on adherence. This study assessed adherence, in daily life, to subcutaneous (sc) IFN beta-1a, self-administered using the RebiSmart® electronic injection device (the IFN beta-Ia autoinjector device), in patients with MS. Patients and methods: This was a retrospective observational study analyzing treatment adherence based on injection data, eg, injection date and dose, extracted from the IFN beta-Ia autoinjector devices collected from patients in Germany and the Netherlands. Results: Data recorded in the period from 2007 to 2012 by the IFN beta-Ia autoinjector devices from 1,682 (79.7% from Germany, 20.3% from the Netherlands) patients were analyzed. A mean of 94.8% of the multi-dose cartridges (containing sc IFN beta-1a for three injections) were used completely, indicating a low incidence of application errors and drug wastage. The mean adherence rate was 90.7% and 82.9% over the entire observation period (mean treatment duration: 150.1 weeks). Median adherence rates were similar between German and Dutch patients (97.9% vs 99.0%). Conclusion: In daily clinical practice, patients using the IFN beta-Ia autoinjector device were highly adherent to sc IFN beta-1a. The injection data stored electronically in the device may help patients to adhere to treatment regimens and, if viewed by physicians, promote discussion of adherence issues with patients. Keywords: multiple sclerosis, injection device, IFN beta-1a, observational study https://www.dovepress.com/patient-adherence-to-subcutaneous-ifn-beta-1a-injections-using-the-reb-peer-reviewed-article-PPAmultiple sclerosisinjection deviceinterferon beta-1aobservational study |
| spellingShingle | Krol M de Voer G Osowski U Patient adherence to subcutaneous IFN beta-1a injections using the RebiSmart® injection device: a retrospective real-world study among Dutch and German patients with multiple sclerosis Patient Preference and Adherence multiple sclerosis injection device interferon beta-1a observational study |
| title | Patient adherence to subcutaneous IFN beta-1a injections using the RebiSmart® injection device: a retrospective real-world study among Dutch and German patients with multiple sclerosis |
| title_full | Patient adherence to subcutaneous IFN beta-1a injections using the RebiSmart® injection device: a retrospective real-world study among Dutch and German patients with multiple sclerosis |
| title_fullStr | Patient adherence to subcutaneous IFN beta-1a injections using the RebiSmart® injection device: a retrospective real-world study among Dutch and German patients with multiple sclerosis |
| title_full_unstemmed | Patient adherence to subcutaneous IFN beta-1a injections using the RebiSmart® injection device: a retrospective real-world study among Dutch and German patients with multiple sclerosis |
| title_short | Patient adherence to subcutaneous IFN beta-1a injections using the RebiSmart® injection device: a retrospective real-world study among Dutch and German patients with multiple sclerosis |
| title_sort | patient adherence to subcutaneous ifn beta 1a injections using the rebismart reg nbsp injection device a retrospective real world study among dutch and german patients with multiple sclerosis |
| topic | multiple sclerosis injection device interferon beta-1a observational study |
| url | https://www.dovepress.com/patient-adherence-to-subcutaneous-ifn-beta-1a-injections-using-the-reb-peer-reviewed-article-PPA |
| work_keys_str_mv | AT krolm patientadherencetosubcutaneousifnbeta1ainjectionsusingtherebismartregnbspinjectiondevicearetrospectiverealworldstudyamongdutchandgermanpatientswithmultiplesclerosis AT devoerg patientadherencetosubcutaneousifnbeta1ainjectionsusingtherebismartregnbspinjectiondevicearetrospectiverealworldstudyamongdutchandgermanpatientswithmultiplesclerosis AT osowskiu patientadherencetosubcutaneousifnbeta1ainjectionsusingtherebismartregnbspinjectiondevicearetrospectiverealworldstudyamongdutchandgermanpatientswithmultiplesclerosis |